Prognostic factors in non-small cell lung cancer

Feld, Ronald; Borges, Maria Cristina Leite Araújo; Giner, Vicente; Ginsberg, Robert J.; Harper, Peter; Klastersky, Jean; Lk, Lacquet; Paesmans, Marianne; Payne, David G.; Rossell, R.; Sause, William T.; Sculier, Jean-Paul; Shaw, Edward G.; Sørensen, Jens Benn; Splinter, Ted A.W.; Stahel, Rolf A.; Bunn, P.

doi:10.1016/0169-5002(94)91861-9

Cited by 33 publications

(22 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been previously determined that stage is an important prognostic factor for NSCLC patients (Capewell et al, 1990;Parkin et al, 1990;Feld et al, 1994;Takigawa et al, 1996;Feld et al, 1997;Sugiura et al, 1997;Birim et al, 2006;Mutlu et al, 2013). This study demonstrated a statistically significant relationship between OS rate and stage in multivariate analysis.…”

Section: Discussionsupporting

confidence: 65%

“…Poor performance affects survival negatively in NSCLC patients (Feld et al, 1980;Stanley et al, 1980;Ruchdeschel et al, 1986;Capewell et al, 1990;Feld et al, 1994;Takigawa et al, 1996;Martins et al, 1999;Necla et al, 2005;Sibel et al, 2010;Inal et al, 2012). In our study, ECOG-PS was an important prognostic factor among the T4 tumor patient group and enhanced median OS rates were achieved for patients with good ECOG-PS situations.…”

Section: Discussionmentioning

confidence: 53%

See 1 more Smart Citation

Survival Results and Prognostic Factors in T4 N0-3 Non-small Cell Lung Cancer Patients According to the AJCC 7^thEdition Staging System

Arslan

Bozcuk²,

Gündüz³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

, and primary treatment (p=0.004) were significant. In the group receiving non-curative treatment, the median OS was 11.0 months, while it was 19.0 months in the definitive RT group and 26.6 months in the curative treatment group. There was a significant difference between the non-curative group and the groups which had definitive RT and curative operations (respectively p<0.001 and p=0.001) in terms of OS, but not between the groups which had definitive RT and curative operations. The median event free survival (EFS) rate was 9.9 months, with rates of 46% and 19% at 3 and 5 years, respectively. On univariate analysis of EFS rate with ECOG-PS, weight loss and staging, statistical significance was found only for thorax computerized tomography (CT)+18F-fluorodeoxy-glucose positron emission tomography-CT (PET-CT) use, stage and primary treatment (p<0.20). In multivariate analysis with EFS, only the primary treatment was statistically significant (p=0.001). In the group receiving non-curative treatment, the median EFS was 10.5 months while in the curative operation group it was 14.7 months. When all the primary treatment groups were taken into consideration, grade III/IV side effect swas observed in 57 patients (46.6%). Esophagitis was most prominent among those that received definitive radiotherapy. Conclusions: Independent prognostic factors among these 122 heterogeneous LA-NSCLC T4 N0-3 M0 patients were age at diagnosis, ECOG-PS, stage and primary treatment, the last also being a significant prognostic indicator of EFS. Our findings point to the importance of appropriate staging and a multidisciplinary approach with modern imaging methods in this patient group. In those with T4 lesions, treatment selection and the effective use of curative potential should be the most important goal of clinical care. (Jemal et al., 2010). Almost 85% of lung cancers fall within the non-small cell (NSCLC) subgroup and many of these are staged as stages IIIA, IIIB or IV during diagnosis Deniz Arslan et al

show abstract

Section: Discussionsupporting

confidence: 65%

Section: Discussionmentioning

confidence: 53%

Survival Results and Prognostic Factors in T4 N0-3 Non-small Cell Lung Cancer Patients According to the AJCC 7^thEdition Staging System

Arslan

Bozcuk²,

Gündüz³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Shinkai et al [11] also demonstrated in 192 patients with inoperable NSCLC a better median survival time for women of 438 days; for men, the survival time was only 273 days. The Consensus Report [14] about prognostic factors in NSCLC classified the gender of patients as a factor of possible prognostic impact. Our finding that sodium is of prognostic value has not yet been verified by other authors.…”

Section: Discussionmentioning

confidence: 99%

“…Because of extremely shortened survival times, these patients need special attention from the physician, who should try to influence their remaining survival time in a therapeutically beneficial manner. The new Consensus Report of 1994 [14] classified the initial stage of disease as a definitive prognostic factor for survival in NSCLC patients. The results of our analysis confirm this.…”

Section: Discussionmentioning

confidence: 99%

“…The type or extent of chemotherapy or combined radiochemotherapy given was not evaluated because the kind of treatment is not a real prognostic factor (pretreatment factor). It should be considered as stratification for second interventions [14]. The date of statistical evaluation was July 1, 1994, so we reached a minimum follow-up time of 3.5 years for all patients.…”

Section: Factors Analyzedmentioning

confidence: 99%

See 1 more Smart Citation

Pretreatment Prognostic Factors for Survival in Non-Small-Cell Lung Cancer: A Multivariate Analysis of 229 Patients

Rechnitzer¹,

Bülzebruck²,

Ébert³

et al. 1998

Oncol Res Treat

View full text Add to dashboard Cite

Lung Cancer

Brundage

Mackillop

2003

TNM Online

View full text Add to dashboard Cite

Lung cancer is best conceptualized as a group of heterogeneous clinical entities with common molecular and cellular origins, but with different clinical behaviors, and hence, different prognoses. Lung cancer has a major impact on population health; taken together, lung cancers are the most common cause of cancer death in both males and females in North America. Overall, only 13% of patients survive more than 5 years after being diagnosed. Determining the prognosis for an individual patient with lung cancer is difficult, in part, because the clinical course of the disease in the individual case can evolve along a seemingly infinite combination of branching pathways. Over 90% of lung cancer patients present with signs or symptoms of disease, and since no symptoms or signs are pathognomonic for lung cancer, the disease has a capacity clinically to mimic other cancers and other nonmalignant diseases with a constellation of possible presenting symptoms. These varying presentations, and potential clinical evolutions, are in turn due to the multiple potential manifestations of the primary tumor, metastatic sites of involvement, and paraneoplastic syndromes. Despite the heterogeneity of the clinical manifestations of lung cancer, the prognosis for a population of patients with lung cancer is remarkably predictable. The overall mortality rates for lung cancer in North America over the last 15 years have remained unchanged. A population‐based study of over 12,000 patients with unresected non‐small‐cell lung cancer registered in seven Ontario Regional Cancer Centers (1982–1991) demonstrated no significant differences in patient survival either between Centers or over time. The predictability of population survival outcomes is of limited usefulness, however, due to the marked heterogeneity of patients making up the overall population. Prognostic factors are thus used to divide the overall population of lung cancer patients into subgroups in order to realize the benefits of prognostic stratification. A number of studies have addressed the identification and application of such factors.

show abstract

Prognostic factors in non-small cell lung cancer

Cited by 33 publications

References 37 publications

Survival Results and Prognostic Factors in T4 N0-3 Non-small Cell Lung Cancer Patients According to the AJCC 7^thEdition Staging System

Survival Results and Prognostic Factors in T4 N0-3 Non-small Cell Lung Cancer Patients According to the AJCC 7^thEdition Staging System

Pretreatment Prognostic Factors for Survival in Non-Small-Cell Lung Cancer: A Multivariate Analysis of 229 Patients

Lung Cancer

Contact Info

Product

Resources

About

Prognostic factors in non-small cell lung cancer

Cited by 33 publications

References 37 publications

Survival Results and Prognostic Factors in T4 N0-3 Non-small Cell Lung Cancer Patients According to the AJCC 7thEdition Staging System

Survival Results and Prognostic Factors in T4 N0-3 Non-small Cell Lung Cancer Patients According to the AJCC 7thEdition Staging System

Pretreatment Prognostic Factors for Survival in Non-Small-Cell Lung Cancer: A Multivariate Analysis of 229 Patients

Lung Cancer

Contact Info

Product

Resources

About

Survival Results and Prognostic Factors in T4 N0-3 Non-small Cell Lung Cancer Patients According to the AJCC 7^thEdition Staging System

Survival Results and Prognostic Factors in T4 N0-3 Non-small Cell Lung Cancer Patients According to the AJCC 7^thEdition Staging System